Luminopia’s Digital Therapeutic Shows Early Promise For Intermittent Exotropia In Small Pilot Study

A digital therapeutic originally developed to treat amblyopia may have broader clinical potential. Early pilot data suggest Luminopia’s dichoptic vision therapy could improve eye alignment control in children with intermittent exotropia, prompting the company to launch a randomized controlled study.

The pilot study enrolled 10 children aged 4 to 7 years, all with intermittent exotropia in one eye. Patients were prescribed one hour per day of Luminopia therapy, six days a week, for three months. Picture Courtesy: Luminopia
Key Takeaways
  • A 10-patient study showed significant improvement in eye alignment control and no regression during washout.  

A prescription digital therapeutic used to treat amblyopia in children may also have clinical utility in intermittent exotropia (IXT), according...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Device Area

GAO Flags Durable Medical Equipment Fraud Risks, Calls For Stronger Medicare Oversight

 

The GAO is urging HHS and CMS to strengthen Medicare fraud risk assessments, citing gaps in oversight and vulnerabilities involving durable medical equipment, prosthetics, orthotics, and supplies. A recent GAO report recommends four steps HHS should take to strengthen its anti-fraud efforts.

US FDA Advisers Wrestle With How To Validate Pathogen-Agnostic Sequencing Before The Next Pandemic

 

The Microbiology Devices Panel took no votes on pathogen-agnostic sequencing, but its talk of validation, thresholds and change control may preview how FDA reviews future tests.

Synchron Pauses Clinical Trial On Brain Interface, Plans To Resume Trial With Upgraded System

 
• By 

Synchron said it paused enrollment in its INTENT trial of the second-generation Stentrode BCI over a lead issue and plans to resume after hardware upgrades are completed.

Cognito Leans On Mild Alzheimer’s Subgroup In FDA Push After Pivotal Trial Misses Endpoints

 
• By 

Cognito Therapeutics signaled it plans to try to work with the US FDA on regulatory authorization for its Spectris AD non-invasive Alzheimer’s treatment, citing slower decline in patients with mild Alzheimer’s. The study showed no treatment benefit for patients whose condition was more advanced.

More from Medtech Insight

Global Regulators Collaborate On AI Medtech Directory, Plan Worldwide Warning System

 

Database from HealthAI network aims to improve international reliance by making information on all approved AI devices publicly available.

Synchron Pauses Clinical Trial On Brain Interface, Plans To Resume Trial With Upgraded System

 
• By 

Synchron said it paused enrollment in its INTENT trial of the second-generation Stentrode BCI over a lead issue and plans to resume after hardware upgrades are completed.

Regulatory Attorneys Outline FDA’s Evolving Approach To Digital Health

 

Squire Patton Boggs attorneys said manufacturers must assess intended use, document regulatory decisions and reassess classifications as products and FDA policies evolve, even as 2026 FDA guidance gives wearables, clinical decision support software and AI tools more flexibility.